Overview

A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids

Status:
Completed

Trial end date:
2017-05-19

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of Relugolix (TAK-385) in patients having pain symptoms associated with uterine fibroids.

Phase:

Phase 3

Details

Lead Sponsor:

Takeda

Treatments:

Relugolix